AU5647099A - Remedal or preventive agent for congestive heart failure - Google Patents

Remedal or preventive agent for congestive heart failure

Info

Publication number
AU5647099A
AU5647099A AU56470/99A AU5647099A AU5647099A AU 5647099 A AU5647099 A AU 5647099A AU 56470/99 A AU56470/99 A AU 56470/99A AU 5647099 A AU5647099 A AU 5647099A AU 5647099 A AU5647099 A AU 5647099A
Authority
AU
Australia
Prior art keywords
remedal
heart failure
congestive heart
preventive agent
preventive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56470/99A
Inventor
Takefumi Gemba
Toshitake Shimamura
Hiroshige Tsuzuki
Fumihiko Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU5647099A publication Critical patent/AU5647099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU56470/99A 1998-09-11 1999-09-08 Remedal or preventive agent for congestive heart failure Abandoned AU5647099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25803398 1998-09-11
JP10/258033 1998-09-11
PCT/JP1999/004859 WO2000015213A1 (en) 1998-09-11 1999-09-08 Remedal or preventive agent for congestive heart failure

Publications (1)

Publication Number Publication Date
AU5647099A true AU5647099A (en) 2000-04-03

Family

ID=17314612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56470/99A Abandoned AU5647099A (en) 1998-09-11 1999-09-08 Remedal or preventive agent for congestive heart failure

Country Status (2)

Country Link
AU (1) AU5647099A (en)
WO (1) WO2000015213A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727266B2 (en) 2000-01-26 2004-04-27 Shionogi & Co., Ltd. Substituted tryptophan derivatives
JP3974781B2 (en) * 2000-04-21 2007-09-12 塩野義製薬株式会社 Oxadiazole derivatives having anticancer activity
AU2001248765A1 (en) * 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
CA2449999C (en) * 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP1419770A4 (en) * 2001-08-24 2005-08-03 Shionogi & Co Apo ai expression accelerating agent
ATE438618T1 (en) 2001-12-14 2009-08-15 Exelixis Inc INHIBITORS OF HUMAN ADAM-10
AU2003239599B8 (en) 2002-05-29 2008-08-14 Merck Sharp & Dohme Corp. Compounds useful in the treatment of anthrax and inhibiting lethal factor
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (en) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
EP1680109A4 (en) 2003-10-07 2009-05-06 Renovis Inc Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA011930B1 (en) 2004-04-07 2009-06-30 Лаборатуар Сероно Са Carboxylic acids
CA2566191A1 (en) 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
US20080119513A1 (en) * 2004-09-06 2008-05-22 Fumihiko Watanabe Sulfonamide Derivative Selectively Inhibiting Mmp-13
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
WO2007102392A1 (en) 2006-03-03 2007-09-13 Shionogi & Co., Ltd. Mmp-13-selective inhibitor
JPWO2008053913A1 (en) 2006-11-02 2010-02-25 塩野義製薬株式会社 Sulfonylurea derivatives that selectively inhibit MMP-13
EP2098226A1 (en) * 2008-03-06 2009-09-09 Forschungsverbund Berlin e.V. AKAP-PKA interaction inhibitors for use in the treatment of heart diseases
ES2575689T3 (en) * 2008-12-23 2016-06-30 Aquilus Pharmaceuticals, Inc Compounds and methods for the treatment of pain and other diseases
EP2681209B1 (en) * 2011-03-02 2018-05-09 Aquilus Pharmaceuticals, Inc Compounds and methods for the treatment of pain and other disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL326700A1 (en) * 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
SK282995B6 (en) * 1996-01-23 2003-01-09 Shionogi And Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing same
KR20000068415A (en) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Compounds for and a Method of Inhibiting Matrix Metalloproteinase
KR20000068414A (en) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Matrix Metalloproteinase Inhibitors and their Therapeutic Uses
IL129147A0 (en) * 1996-10-16 2000-02-17 American Cyanamid Co The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
NZ502274A (en) * 1997-07-22 2001-03-30 Shionogi & Co The use of a therapeutic or prophylactic agent containing a sulphonamide derivative for treating glomerulopathy
JPH11246527A (en) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Mmp-8 inhibitor

Also Published As

Publication number Publication date
WO2000015213A1 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
AU5647099A (en) Remedal or preventive agent for congestive heart failure
AU2879299A (en) Controlling congestive heart failure
AU3430199A (en) Echo cancellation
AU1827600A (en) Non-corrosive sterilant composition
AU1424200A (en) Compounds
AU4501699A (en) Aminoazole compounds
AU3266199A (en) Elevator
AU4900699A (en) Herbicidal composition
AU3344099A (en) Analgetic agent
AU1319600A (en) Multilayer structures
AU1434500A (en) Compounds
AU7432698A (en) Disinfectant composition
AU5516599A (en) Substituted 3-aryl-pyrazoles
AUPP182498A0 (en) Welding equipment
AU4511499A (en) Substituted cyclooctadepsipeptides
AU5844196A (en) Remedy or preventive for hyperlipemia
AU6006099A (en) Preventives or remedies for cachexia
AU2178997A (en) Preventive or remedy for kidney diseases
AU2512099A (en) Elevator
AU1575200A (en) Elevator
AU2725599A (en) Substituted alxoxycarbonyl compounds
AU8561398A (en) Herbicidal composition
AU5661399A (en) Compounds
AU4761099A (en) Multi-layer fire-protection component
AU3032299A (en) Fungicidal benzoheterocyclyloxime

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase